Article
Pharmacology & Pharmacy
Jianing Chen, Yaokai Wen, Xiangling Chu, Yuzhi Liu, Chunxia Su
Summary: This study revealed the unique adverse event profile of NSCLC patients with hypertension receiving anti-PD-1/PD-L1 inhibitors, showing that patients with hypertension were more prone to reporting interstitial lung disease when undergoing anti-PD-1 treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Zhaodan Xin, Liting You, Feifei Na, Jin Li, Min Chen, Jiajia Song, Ling Bai, Jie Chen, Juan Zhou, Binwu Ying
Summary: In this study, the researchers identified several immunogenetic variants associated with immune-related adverse events (irAEs) and irAEs-free survival in patients treated with PD-1/PD-L1 inhibitors, which could serve as potential predictive biomarkers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Woorim Kim, Young-Ah Cho, Dong-Chul Kim, A-Ra Jo, Kyung-Hyun Min, Kyung-Eun Lee
Summary: This study aims to investigate factors associated with thyroid dysfunction in cancer patients receiving PD-1/PD-L1 inhibitors and develop machine learning approaches to predict complications. The results showed smoking history, hypertension, and opioids are associated with thyroid-related adverse events. Machine learning models, particularly random forest, demonstrated good predictive performance for such events.
Article
Medicine, General & Internal
You-Cheng Zhang, Tian-Chen Zhu, Run-Cong Nie, Liang-He Lu, Zhi-Cheng Xiang, Dan Xie, Rong-Zhen Luo, Mu-Yan Cai
Summary: A meta-analysis study found that early immune-related adverse events (irAEs) are associated with patient survival in the treatment of immune checkpoint inhibitors (ICIs). The study included 11 reports and 2077 patients, and the results showed that early irAEs are correlated with better clinical outcomes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Guili Huang, Songqing Liu, Jie Dong, Xin Xi, Rui Kong, Wenjun Li, Qian Du
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their toxicities, known as immune-related adverse events (irAEs), have not been fully evaluated. This study found differences in the occurrence of irAEs among different types of ICIs, with higher rates associated with sintilimab and pembrolizumab. Lung cancer and cumulative treatment cycles were identified as independent risk factors for irAEs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Yiqing Huang, Yu Yang Soon, Folefac Aminkeng, Sen Hee Tay, Yvonne Ang, Adrian C. L. Kee, Boon Cher Goh, Alvin S. C. Wong, Ross A. Soo
Summary: This study analyzed IrAEs in NSCLC patients receiving immunotherapy, and found that concomitant chemotherapy use, higher BMI, and the presence of EGFR mutation were significant predictors for IrAEs.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Letter
Oncology
Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, Ayako Furugen, Yoh Takekuma, Naofumi Shinagawa, Yasushi Shimizu, Hirotoshi Dosaka-Akita, Mitsuru Sugawara, Masaki Kobayashi
Summary: Patients treated with immune checkpoint inhibitors (ICIs) may develop immune-related adverse events (irAEs) in various organs of the body, and skin irAEs may serve as a predictive marker for the development of multisystem irAEs. Therefore, patients with skin irAEs should be treated and monitored for other types of irAEs.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Immunology
Wenru Qin, Linlin Yang, Bingjie Fan, Bing Zou, Yanan Duan, Butuo Li, Linlin Wang
Summary: This study explores the association between immune-related adverse events (irAEs) caused by PD-1 inhibitors and treatment outcomes in esophageal cancer (EC) patients. The results show that patients with irAEs have significantly better objective response rate, disease control rate, progression-free survival, and overall survival compared to those without irAEs.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Luisa Maria Griewing, Claudia Schweizer, Philipp Schubert, Sandra Rutzner, Markus Eckstein, Benjamin Frey, Marlen Haderlein, Thomas Weissmann, Sabine Semrau, Antoniu-Oreste Gostian, Sarina K. Mueller, Maximilian Traxdorf, Heinrich Iro, Jian-Guo Zhou, Udo S. Gaipl, Rainer Fietkau, Markus Hecht
Summary: Immune checkpoint inhibitors (ICI) are standard treatments for various tumors, but early detection of immune-related adverse events (irAE) is crucial. This study found that questionnaires can help detect gastrointestinal, lung, endocrine, or skin irAE, but not hepatic irAE. Weight change and insomnia questions may increase irAE detection rate.
Review
Cell & Tissue Engineering
Jing Chen, Yaser Alduais, Baoan Chen
Summary: PD-1/PD-L1 inhibitors show potential therapeutic effects in NSCLC treatment, but come with toxicities. Antibody-based therapies can improve overall survival rates but may lead to systemic adverse effects. Targeting specific biomarkers can help reduce the toxicity of antibody-mediated therapy.
CELL TRANSPLANTATION
(2021)
Review
Immunology
Qinan Yin, Liuyun Wu, Lizhu Han, Xingyue Zheng, Rongsheng Tong, Lian Li, Lan Bai, Yuan Bian
Summary: Since the development of the first Immune Checkpoint Inhibitor, tumor immunotherapy has advanced significantly, leading to improved response rate and survival rate in many cancers. However, resistance and immune-related adverse events remain as challenges in achieving lasting response. This article summarizes the mechanisms of immune checkpoint inhibitors, different types of immune-related adverse events, and provides strategies and targets for prevention and therapeutic interventions.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song, Daniel H. Johnson, Chrystia M. Zobniw, Van A. Trinh, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M. Elsayes, Kaysia Ludford, Emma J. Montazari, Julia Chernis, Maya Dimitrova, Sabina Sandigursky, Jeffrey A. Sparks, Osama Abu-Shawer, Osama Rahma, Uma Thanarajasingam, Ashley M. Zeman, Rafee Talukder, Namrata Singh, Sarah H. Chung, Petros Grivas, May Daher, Ala Abudayyeh, Iman Osman, Jeffrey Weber, Jean H. Tayar, Maria E. Suarez-Almazor, Noha Abdel-Wahab, Adi Diab
Summary: This retrospective study evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) therapy for immune-related adverse events (irAEs). The results showed that anti-IL-6R treatment can improve irAEs without hindering antitumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Endocrinology & Metabolism
Jee Hee Yoon, A. Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
Summary: Thyroid immune-related adverse events are common in cancer patients treated with PD-1/PD-L1 inhibitors, with the majority of patients being able to recover normal thyroid function. However, some patients may progress to overt hypothyroidism and require thyroid hormone replacement therapy. Risk factors for developing overt hypothyroidism include higher baseline thyroid stimulating hormone levels and longer duration of therapy.
ENDOCRINOLOGY AND METABOLISM
(2021)
Article
Immunology
Ziqi Ye, Shiyu Zheng, Jie Chen, Yanfang Zhang, Si Yang, Yun Hong, Hongyu Yang, Zixue Xuan, Qingwei Zhao
Summary: The efficacy of PD-1/PD-L1 inhibitors is positively correlated with immune-related adverse events (irAEs), suggesting that irAEs could potentially predict anti-tumor efficacy. Factors such as adipose tissue, T cells, pharmacokinetic characteristics, and antigen spread may contribute to this correlation. The severity of irAEs, duration of drug use, assessment methods, and genetic determinants are important bias factors in evaluating this correlation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Eniko Sebestyen, Nora Major, Levente Bodoki, Attila Makai, Ingrid Balogh, Gabor Toth, Zsuzsanna Orosz, Peter Arkosy, Attila Vasko, Katalin Hodosi, Zoltan Szekanecz, Eva Szekanecz
Summary: This study assessed patients with malignancies who underwent anti-PD-1 treatment at the University of Debrecen, Clinical Center. The study found that immune-related adverse events (irAEs) may be associated with the number of treatment cycles and the type of treated malignancy.
FRONTIERS IN ONCOLOGY
(2023)
